On March 11, Genomeprecision, invested by ZGC Collaborative Innovation Direct Investment Fund, a member of ZGC Development Group, obtained a sales license for its TERT Gene Mutation Assay Kit (fluorescent PCR-capillary electrophoresis sequencing) from NMPA.

These assay kits, based on Sanger sequencing platform, can ensure the maximum accuracy of detection results. Through capillary electrophoresis sequencing, the amplified PCR fragments are analyzed for mutations at the locus of 1295228 and 1295250 in promoter regions of TERT gene. The assay results can inform clinical auxiliary diagnosis, providing reference for clinicians in diagnosis and treatment.

Genomeprecision’s IDH1 Gene Mutation Detection Kit was also approved by NMPA for marketing not long ago. Those two test kits have further diversified the group of gene testing products for related diseases and laid a solid foundation for accurate classification of diseases. At the same time, it also marks the phased victory of the molecular diagnosis layout of Genomeprecision, providing a firm basis for Genomeprecision to become a leading player in the field of precision medicine.